XML 36 R27.htm IDEA: XBRL DOCUMENT v3.23.3
Segment Reporting (Tables)
 9 Months Ended
Sep. 30, 2023
Segment Reporting [Abstract]  
Schedule of Segment Revenue and Operating Income
The following tables present financial information for each reportable segment (in millions):
Three Months Ended September 30,Nine Months Ended September 30,
2023202220232022
Revenues:
Surgical Facility Services$657.3 $603.9 $1,956.5 $1,780.6 
Ancillary Services16.8 16.7 51.4 51.6 
Total$674.1 $620.6 $2,007.9 $1,832.2 
Adjusted EBITDA:
Surgical Facility Services$138.6 $110.2 $384.1 $319.9 
Ancillary Services(1.2)(1.5)(2.7)(2.2)
All other(31.9)(12.5)(85.6)(58.3)
Total$105.5 $96.2 $295.8 $259.4 
Reconciliation of Adjusted EBITDA:
Income before income taxes$32.8 $13.4 $82.3 $77.1 
Net income attributable to non-controlling interests(34.6)(30.6)(99.5)(94.9)
Interest expense, net49.8 60.7 144.3 173.9 
Depreciation and amortization28.9 29.8 87.0 85.2 
Equity-based compensation expense4.4 5.0 13.2 13.0 
Transaction, integration and acquisition costs (1)
13.0 13.1 38.8 28.4 
Net loss on disposals, consolidations and deconsolidations5.8 2.2 7.5 3.2 
Litigation settlements and regulatory change impact (2)
4.2 1.5 13.9 (27.6)
Undesignated derivative activity— — 0.6 — 
Other (3)
1.2 1.1 7.7 1.1 
Adjusted EBITDA$105.5 $96.2 $295.8 $259.4 
(1)This amount includes transaction and integration costs of $12.8 million and $12.5 million for the three months ended September 30, 2023 and 2022, respectively. This amount further includes start-up costs related to de novo surgical facilities of $0.2 million and $0.6 million for the three months ended September 30, 2023 and 2022, respectively.
This amount includes transaction and integration costs of $37.3 million and $27.8 million for the nine months ended September 30, 2023 and 2022, respectively. This amount further includes start-up costs related to de novo surgical facilities of $1.5 million and $0.6 million for the nine months ended September 30, 2023 and 2022, respectively.
(2)This amount includes a litigation settlement loss of $3.6 million for the three months ended September 30, 2023. This amount also includes other litigation costs of $0.6 million and $1.5 million for the three months ended September 30, 2023 and 2022, respectively.
This amount includes a litigation settlement loss of $8.1 million and a gain of $32.8 million for the nine months ended September 30, 2023 and 2022, respectively. This amount also includes other litigation costs of $1.4 million and $5.2 million for the nine months ended September 30, 2023 and 2022, respectively. Additionally, the nine months ended September 30, 2023, includes $4.4 million related to the impact of recent changes in Florida law regarding the use of letters of protection.
(3)This amount includes estimates for the net impact of the May 2023 cyber event for the three months ended September 30, 2023.This amount includes estimates for the net impact of a cyber event and losses from a divested business for the nine months ended September 30, 2023.
Amounts presented for the three and nine months ended September 30, 2022 reflect losses incurred, net of insurance proceeds received, related to certain surgical facilities that were closed following Hurricane Ian.
Schedule of Reconciliation of Assets from Segment to Consolidated
September 30,
2023		December 31,
2022
Assets:
Surgical Facility Services$6,183.9 $6,001.1 
Ancillary Services38.1 41.7 
All other558.1 639.3 
Total assets$6,780.1 $6,682.1 
Schedule of Financial Information by Reportable Segment
Nine Months Ended September 30,
20232022
Cash purchases of property and equipment:
Surgical Facility Services$68.4 $52.8 
Ancillary Services0.6 0.4 
All other— 4.7 
Total cash purchases of property and equipment$69.0 $57.9